Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProSomnus, Inc. - Common Stock (NQ: OSA )

5.145 +0.055 (+1.08%)
Streaming Delayed Price Updated: 3:46 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,640
Open 5.130
Bid (Size) 5.070 (2)
Ask (Size) 5.220 (1)
Prev. Close 5.090
Today's Range 5.040 - 5.145
52wk Range 4.570 - 9.410
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
Earnings Scheduled For March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. 
Via Benzinga

Performance

YTD
-12.14%
-12.14%
1 Month
+0.29%
+0.29%
3 Month
-14.11%
-14.11%
6 Month
-24.34%
-24.34%
1 Year
-24.34%
-24.34%

More News

Read More
ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
ProSomnus to Present at Two Upcoming Investor Conferences in March 2023
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
ProSomnus® Appoints Brian Dow as Chief Financial Officer
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
ProSomnus® Provides Business Update and Preliminary 2022 Revenue Guidance
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
EXCLUSIVE: ProSomnus Expands In Medical Device Industry With Strong 2022 Results, What You Need To Know
Via Benzinga
ProSomnus® Announces Acceptance of Abstract for Oral Presentation at Prestigious American Thoracic Society 2023 International Conference
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
ProSomnus® Announces Completion of Enrollment in Antwerp University Hospital’s First Line Obstructive Sleep Apnea Treatment Study (FLOSAT)
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
EXCLUSIVE: ProSomnus Concludes Enrollment In Head To Head Study Comparing Its Sleep Device With Philips'
Via Benzinga
ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
ProSomnus® Announces Medicare Reimbursement for ProSomnus EVO® [PH] Sleep Apnea and Snoring Device
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Study Published in "Military Medicine" Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy
From ProSomnus Sleep Technologies, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.